Legend Biotech Corporation looks like a J&J acquisition target as Carvykti sales surge and Phase 2 data impress. Click for ...

What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for it? Bryan Roberts ...

The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger ...

Century Therapeutics (IPSC) analysis: autoimmune CAR-cell pivot, CNTY-813 Type 1 diabetes upside, cash burn cuts, rNPV fair ...

This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen ...

ORLANDO, FL / ACCESS Newswire / April 21, 2026 / RedChip Companies, an industry leader in investor relations, media, ...

10x Science, founded in December 2025, has secured $4.8 million in seed funding led by Initialized Capital to address a key ...

Legend Biotech (NASDAQ: LEGN) was one of the healthier healthcare stocks on the market as the trading week kicked off on ...

Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...

But in the last three years, the company has sought to leverage its footholds in China and the U.S. to become a multinational ...

The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.

However, Moderna's deep pipeline and innovative technology could eventually allow it to improve and deliver excellent returns ...